GCH1抗体—艾普蒂

The GCH1 antibody targets GTP cyclohydrolase 1 (GCH1), a rate-limiting enzyme in tetrahydrobiopterin (BH4) biosynthesis. BH4 is a critical cofactor for neurotransmitters (e.g., dopamine, serotonin) and nitric oxide synthesis, linking GCH1 to neurological and vascular functions. GCH1 mutations cause hereditary dopa-responsive dystonia (DRD), characterized by movement disorders and treatable with L-DOPA. In research, GCH1 antibodies are used to study protein expression in tissues or cells via techniques like Western blotting, immunohistochemistry, or immunofluorescence. These tools help explore GCH1's role in neuroprotection, pain regulation, cardiovascular health, and immune responses. Dysregulated GCH1/BH4 pathways are implicated in neurodegenerative diseases (e.g., Parkinson’s), chronic pain syndromes, hypertension, and endothelial dysfunction. Antibody-based studies also investigate GCH1 as a biomarker or therapeutic target, particularly in conditions involving oxidative stress or inflammation. Commercially available GCH1 antibodies are typically validated in human, mouse, or rat models, with specificity confirmed through knockout controls. Ongoing research aims to clarify GCH1's dual roles in physiological homeostasis and disease pathogenesis, highlighting its potential in precision medicine and drug development.